FDA Grants Fast Track Designation to Lipocine for LPCN 1148 as a Treatment for Sarcopenia in Patients with Decompensated Cirrhosis

XOI Index   1,729  2.45  0.14%   
About 56% of ARCA Oil's investor base is looking to short. The analysis of the overall investor sentiment regarding ARCA Oil suggests that many traders are alarmed. The current market sentiment, together with ARCA Oil's historical and current headlines, can help investors time the market. In addition, many technical investors use ARCA Oil index news signals to limit their universe of possible portfolio assets.
ARCA Oil index news, alerts, and headlines are usually related to its technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of ARCA daily returns and investor perception about the current price of ARCA Oil as well as its diversification or hedging effects on your existing portfolios.
Lipocine Inc. , a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced that the U.S. Food and Drug Administration has granted Fast Track Designation to LPCN 1148 as a treatment for sarcopenia in patients with decompensated cirrhosis. LPCN 1148, an oral prodrug of bioidentical testosterone, was recently studied in a proof-of-concept Phase 2 study in patients with decompensated

Read at finance.yahoo.com
Yahoo News
  

ARCA Oil Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with ARCA Oil index to make a market-neutral strategy. Peer analysis of ARCA Oil could also be used in its relative valuation, which is a method of valuing ARCA Oil by comparing valuation metrics with similar companies.